Epcoritamab-CAR T Cells for Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

Trial Details

NCT ID
NCT06458439
Phase
PHASE2
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Epcoritamab
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Age \> 18 years
  • Subject must be able and willing to provide informed consent. In the case where the patient is incapacitated or not otherwise capable, a legally au…
  • Able to comply with the study protocol, in the investigator's judgment
  • ECOG PS of 0 - 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →